Heyholder

This is an amended filing · View original →

‹ Activism Filings

SAMSUNG BIOLOGICS CO.,LTD. Rights offering price set at KRW 1,174,000 for 2,270,000 new shares

SAMSUNG BIOLOGICS CO.,LTD.· Material Event ReportAmended

AI summary · Not investment advice

The company finalized the issue price at KRW 1,174,000 per share for 2,270,000 new shares, with payment due on November 17, 2026.

New shares · common

2,270,000 shares

Key facts

Issue price per share
KRW 1.2 millionFinal issue price
Offering method
Rights offering to existing shareholders, with unsubscribed shares offered to the general public
Acquisition of other securities
KRW 2.7 trillion
New share listing date
Nov 30, 2026
Allotment record date
Oct 6, 2026
Payment date
Nov 17, 2026
Board resolution date
Aug 28, 2026
Shareholder subscription period
Nov 9, 2026 – Nov 10, 2026
Lead manager
Shinhan Investment Corp., NH Investment & Securities, Korea Investment & Securities, KB Securities

Commentary

AI commentary · Not investment advice

What happened

Samsung Biologics decided to issue 2,270,000 new common shares to raise KRW 2,664.98 billion. The money will be used to acquire securities of other companies. Existing shareholders get the first right to buy. Shares they do not take up (forfeited shares) will be offered to the general public. The issue price is KRW 1,174,000 per share. Before this issue, the company had 46,290,951 common shares. The lead underwriters are Shinhan Investment, NH Investment & Securities, Korea Investment & Securities and KB Securities.

In the company's terms

Each existing share receives 0.0392737657 new shares. The record date for allocation is October 6, 2026. The right to buy new shares can be transferred to others. 20.0% is allocated first to the employee stock ownership association.

What changes for shareholders

The subscription period for existing shareholders is confirmed as November 9 to November 10, 2026. Payment is due on November 17, 2026. The new shares are scheduled to be listed on November 30, 2026. The board approved the plan on August 28, 2026.

Earlier Material Event Report filings from this company

Filings of the same type
FiledTitleKey figure · Note
22.01.28[Amended] Material Event ReportKRW 2.7 trillion · 36.32% of equity; based on a tender price of CHF 44.31 per share; actual amount may vary with the tender result and exchange rate

Comments

No comments yet

Comments from shareholders will appear here.